Class / Patent application number | Description | Number of patent applications / Date published |
514210160 | Polycyclo ring system having the four-membered hetero ring as one of the cyclos | 87 |
20090036422 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS - The present invention relates to compounds of formula | 02-05-2009 |
20090124595 | MAPK/ERK KINASE INHIBITORS - Compounds of the following formula are provided for use with MEK: | 05-14-2009 |
20090156575 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES - The invention provides compounds of general formula | 06-18-2009 |
20090197860 | BIARYL SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES - The invention relates biaryl substituted diazabicycloalkanes, and more particularly bicycloheteroaryl substituted fused diazabicycloalkane derivatives, compositions comprising such compounds, and methods of preventing or treating conditions and disorders using such compounds and compositions. | 08-06-2009 |
20090203664 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6- DIAZABICYCLO[3.2.0]HEPTANE - The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor. | 08-13-2009 |
20090264403 | NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS - The invention relates to azacyclyl-substituted aryldihydroisoquinolinones and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one azacyclyl-substituted aryldihydroisoquinolinone of the invention or its derivative, and the use of the azacyclyl-substituted aryidihydroisoquinolinones of the invention and their derivatives as MCH antagonists. | 10-22-2009 |
20090281073 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS - This invention relates to compounds of Formula (I), and to pharmaceutically acceptable salts and solvates thereof, wherein Z, W, X, Y, V, R | 11-12-2009 |
20090318406 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS - The present invention relates to novel oxindole derivatives of general formula (I), | 12-24-2009 |
20100009958 | QUINAZOLINE DERIVATIVES - Quinazoline derivatives of the following formula: | 01-14-2010 |
20100009959 | Pentacyclic Indole Derivatives as Antiviral Agents - The present invention relates to pentacyclic indole derivatives of formula (I): wherein A, Ar, R | 01-14-2010 |
20100016277 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS - Compounds of formula I | 01-21-2010 |
20100048531 | GlyT1 RECEPTOR ANTAGONISTS - The present invention relates to a compound of formula I | 02-25-2010 |
20100093691 | TOPICAL FORMULATIONS - There is provided topical pharmaceutical compositions comprising compounds of formula I | 04-15-2010 |
20100144700 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS - A compound of Formula 1: A-C(O)-Cy, wherein A is a diazabicyclic core, containing 7, 8, or 9 ring atoms, and selected from the following: 2,6-diazabicyclo[3.2.0]heptane; 3,6-diazabicyclo[3.ZO]heptane; 2,7-diazabicyclo[4.2.0]octane; 3,7-diazabicyclo[4.2.0]octane; 3,8-diazabicyclo[4.2.0]octane; 2,7-diazabicyclo[3.3.0]octane; 2,7-diazbicyclo[4.3.0]nonane; 2,8-diazbicyclo[4.3.0]nonane; 3,7-diazabicyclo[4.3.0]nonane; 3,8-diazabicyclo[4.3.0]nonane; 3,9-diazabicyclo[4.3.0]nonane; 2,6-diazabicyclo[3.2.1]octane; 3,6-diazabicyclo[3.2.1]octane; wherein the diazabicycle is attached as a radical to the depicted carbonyl via either one of the two ring nitrogen atoms, such that the carbonyl forms an amide bond with the ring nitrogen; Cy is a heteroaryl group; The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α402 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds are believed to: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects, namely side effects such as significant Increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle. | 06-10-2010 |
20100152157 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF - The invention relates to the 6-cycloamino-3-(pyridazin-4-yl)imidazo[I,2-b]pyridazine derivatives corresponding to general formula (I): | 06-17-2010 |
20100190763 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors - Disclosed are compounds of the following formula: | 07-29-2010 |
20100204197 | PYRROLOPYRIMIDINES - The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are polo-like kinase (PLKs) inhibitors useful for the treatment of disease states mediated by PLK, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumour growth, rheumatoid arthritis, restenosis and atherosclerosis. | 08-12-2010 |
20100280000 | THERAPEUTIC AGENTS 713 - Disclosed herein are compounds of formula I | 11-04-2010 |
20100305089 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives - The invention relates to fused bicycloheterocycle substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. | 12-02-2010 |
20100331294 | 4-SUBSTITUTED-2-AMINO-PYRIMIDINE DERIVATIVES - Compounds of the formula | 12-30-2010 |
20110028444 | PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTI-INFECTION QUINOLONE COMPOUNDS - The invention discloses the pharmaceutically acceptable salts of an optically active quinolone compound useful against infection, specifically the pharmaceutically acceptable salts of (S)-6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid. The pharmaceutically acceptable salts of the present invention are stable and have improved water solubility. They possess higher biological activity, less toxicity for kidney and no irritation to skin and muscle. | 02-03-2011 |
20110071128 | NOVEL IMIDAZOPYRIDINES - The invention is concerned with novel imidazopyridine derivatives of formula (I) | 03-24-2011 |
20110071129 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE - [Problem] To provide a melanin concentrating hormone receptor antagonist useful as medicines for central system disorders, cardiovascular disorders, metabolic disorders. | 03-24-2011 |
20110086834 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS - Selected compounds are effective for prophylaxis and treatment of inflammation and inflammatory disorders, such as NIK-mediated disorders. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, inflammation and the like. | 04-14-2011 |
20110092475 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME - The present invention provides 2-substituted-ethynylthiazole derivatives of formula (I): | 04-21-2011 |
20110098270 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE - Thiazolopyrimidine compounds of formula I, where W represents a thiazole ring, selectively inhibit the p110 delta subtype of PI3 Kinase (PI3K), and are useful for treating diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders. | 04-28-2011 |
20110118230 | DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 05-19-2011 |
20110136778 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF - A compound of the following general formula [I]: | 06-09-2011 |
20110152237 | Chemical Compounds - Disclosed are compounds of Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts. | 06-23-2011 |
20110152239 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE - The present invention relates to a process for preparing compositions of high concentrations of omega-3 fatty acids from krill. Furthermore, the invention relates to a composition comprising high concentrations of omega-3 fatty acids, and a lipid fraction from krill comprising high amounts of the fatty acids with chain length C14 and C 16. | 06-23-2011 |
20110207711 | Therapeutic Compounds - The present invention relates to pyrazolopyridines and imidazopyridines which are inhibitors of the kinase PDK1 and are thus useful for the treatment of myeloproliferative disorders or cancer. The compounds are also useful as inhibitors of other kinases such as FGFR3, NTRK3, RP-S6K and WEE1. Furthermore, the present compounds also selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. | 08-25-2011 |
20110212937 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION - The present disclosure provides a series of compounds of the formula (I) | 09-01-2011 |
20110230461 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES - The present invention provides a compound of Formula (I) | 09-22-2011 |
20110288067 | Pyrrolopyrazine Kinase Inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 11-24-2011 |
20110301141 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS - Compounds of the formula I: | 12-08-2011 |
20110306587 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS - Unsaturated nitrogen heterocyclic compounds of formula (I): | 12-15-2011 |
20110306588 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS - Heteroaryloxyheterocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like. | 12-15-2011 |
20110306589 | NITROGEN CONTAINING HETEROARYL COMPOUNDS - The invention is concerned with novel nitrogen-containing heteroaryl compounds of formula (I) | 12-15-2011 |
20120028952 | 5-ALKYNYL-PYRIMIDINES - The present invention encompasses compounds of general formula (1) | 02-02-2012 |
20120040949 | Inhibitors of Bruton's Tyrosine Kinase - This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: | 02-16-2012 |
20120077795 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS - The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and diabetes. | 03-29-2012 |
20120115839 | USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS - The present invention relates to the pharmaceutical use of selective GABA A α5 negative allosteric modulators for the treatment, prevention and/or delay of progression of central nervous system (CNS) conditions related to excessive GABAergic inhibition in the brain. | 05-10-2012 |
20120122835 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors - Disclosed are compounds of the following formula: | 05-17-2012 |
20120149675 | 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS - The present invention is concerned with novel 1,2,3-triazole-imidazole compounds of formula (I) | 06-14-2012 |
20120149676 | NOVEL COMPOUNDS - This invention relates to compounds of formula I | 06-14-2012 |
20120149677 | ETHER BENZOTRIAZOLE DERIVATIVES - The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved. | 06-14-2012 |
20120157428 | BROMODOMAIN INHIBITORS AND USES THEREOF - The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders. | 06-21-2012 |
20120172346 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS - The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease. | 07-05-2012 |
20120202782 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb). | 08-09-2012 |
20120202783 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS - Disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo[3.2.0]heptane compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia. | 08-09-2012 |
20120232048 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS - A method of modulating the activity of the GPR119 G protein-coupled receptor comprising administering to a mammalian patient in need thereof a therapeutically effective amount of at least one compound of Formula I or Formula IA and, optionally, an additional therapeutic agent. | 09-13-2012 |
20120295882 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions - This application relates to tricyclic compounds of Formula I: | 11-22-2012 |
20120309737 | 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands - The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS). | 12-06-2012 |
20120329772 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE - A compound having Formula (I) or Formula (II) | 12-27-2012 |
20130005703 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN-5-HT6 RECEPTOR - The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT | 01-03-2013 |
20130079323 | GYRASE INHIBITORS - Novel gyrase inhibitors and related compositions and methods are useful for impeding bacterial growth. Compounds of Formula (I), are disclosed: Formula (I), wherein Y is N or CH; Z is N or CR | 03-28-2013 |
20130109668 | AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | 05-02-2013 |
20130137672 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS - Certain disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo[3.2.0]heptane are described, which are useful as orexin inhibitors. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia. | 05-30-2013 |
20130190288 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS - Compounds of the formula I: | 07-25-2013 |
20130217661 | QUINAZOLINE DERIVATIVES - Quinazoline derivatives of the following formula: | 08-22-2013 |
20130225549 | DIHYDROPTERIDINONES I - The present invention relates to dihydropteridinones, their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which interfere with γ-secretase and/or its substrate and therefore modulate the formation of Aβ peptides. | 08-29-2013 |
20130274239 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS - Disclosed are compounds of the following formula: | 10-17-2013 |
20130296295 | BCL-2 SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein. | 11-07-2013 |
20140073622 | IMIDAZOLE CARBONYL COMPOUND - To develop an antibiotic having a novel mechanism of action, the present inventors have searched for a compound that has weak cytotoxicity, the physical property of high solubility in water, the effect of inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and sufficient antibacterial activity. As a result, the present inventors have completed the present invention by finding that a compound of the present invention represented by the general formula (1), a pharmacologically acceptable salt thereof, and a prodrug thereof have desirable properties. The present invention provides a pharmaceutical composition (particularly, a preventive or therapeutic composition for infectious disease) comprising a compound represented by the formula (1), a pharmacologically acceptable salt thereof, or a prodrug thereof as an active ingredient. | 03-13-2014 |
20140073623 | Tricyclic Sulfonamide Compounds and Methods of Making and Using Same - The invention provides tricyclic sulfonamide compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 03-13-2014 |
20140121193 | METHODS FOR TREATING FIBROMYALGIA - The invention provides methods for treating or ameliorating cognitive dysfunction, fatigue, energy, concentration, mood, and pain associated with fibromyalgia using compositions containing methylphenidate or pharmaceutically equivalents thereof. | 05-01-2014 |
20140206661 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS - The present invention provides a compound of Formula (X) or a pharmaceutically acceptable salt thereof; | 07-24-2014 |
20140249129 | Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase Activity - This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 | 09-04-2014 |
20140288042 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - This invention relates to compounds of Formula I having the following general structure: | 09-25-2014 |
20140315880 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS - The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS). | 10-23-2014 |
20140323462 | AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Provided are compounds of Formula I, | 10-30-2014 |
20140336166 | NOVEL PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE - The invention relates to PI3K inhibitors of the formula (I) • in which all of the variables are as defined in the specification, to their preparation, to their medical use, in particular to their use in the treatment of cancer and neurodegenerative disorders, and to medicaments comprising them. | 11-13-2014 |
20140343032 | NOVEL 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION - The invention provides novel compounds having the general formula: | 11-20-2014 |
20140343033 | AZAINDOLE DERIVATIVES - Disclosed are compounds of Formula 1, | 11-20-2014 |
20140349987 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES - The invention provides modulators for the orphan nuclear receptor ROR | 11-27-2014 |
20150315209 | HETEROCYCLIC COMPOUND - An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: | 11-05-2015 |
20160022658 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE - The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an α4β2 positive allosteric modulator, a method of using the same, and a related article of manufacture. | 01-28-2016 |
20160108027 | SUBSTITUTED BENZOXAZOLES - The invention relates to substituted benzoxazoles and to processes for their preparation and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders, preferably of thrombotic or thromboembolic disorders. | 04-21-2016 |
20160108039 | TRIAZOLOPYRIDINES AS THROMBIN INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES - The invention relates to substituted triazolopyridines and to processes for their preparation and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders, preferably of thrombotic or thromboembolic disorders. | 04-21-2016 |
20160115126 | INDOLE CARBOXAMIDE COMPOUNDS - Disclosed are compounds of Formula (I): | 04-28-2016 |
20160122363 | NOVEL 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION - The invention provides novel compounds having the general formula: | 05-05-2016 |
20160137647 | SUBSTITUTED BENZOXAZOLES - The invention relates to substituted benzoxazoles and to processes for their preparation and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders, preferably of thrombotic or thromboembolic disorders. | 05-19-2016 |
20160185780 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein. | 06-30-2016 |
20160376277 | NOVEL HETEROCYCLIC COMPOUNDS - The present invention relates to heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as selective Bruton's Tyrosine Kinase (BTK) inhibitors. | 12-29-2016 |
20160376283 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF - The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors. | 12-29-2016 |
20220135557 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - A RET inhibitor, a pharmaceutical composition thereof and uses thereof including a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Furthermore, a pharmaceutical composition including the compound, and uses of the compound and pharmaceutical composition thereof in the manufacture of a medicament for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome. | 05-05-2022 |
20220135584 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF - The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same. | 05-05-2022 |